Top Markets
#1 ADO Protocol ADO Protocol +328.82%
#2 GoPlus Security GoPlus Security +57.25%
#3 Starpower Starpower +44.49%
#4 Tutorial Tutorial +34.66%
#5 Verus Coin Verus Coin +33.62%
#6 Nockchain Nockchain +31.92%
#7 Chainflip Chainflip +28.11%
#8 The Black Bull The Black Bull +25.66%
#9 GAIB AID GAIB AID +24.67%
#10 Casper Network Casper Network +16.94%
Coin of the day
ADO Protocol ADO Protocol
Settings
Language
ENGLISH
Currency
USD
Theme
Pharmena S.a. Pharmena S.a.

Pharmena S.a.

PHR
Rank in Stocks #32515
Pharmena S.A. engages in the sale of dietary supplements in Poland and... Pharmena S.A. engages in the sale of dietary supplements in Poland and internationally. It also develops 1-MNA (PHR-701 program), a medical device for use in difficult-to-heal wounds. In addition, the company is involved in research and development of therapeutic applications of 1 MNA as an anti-inflammatory and anti-fibrotic drug; and research and development at pulmonary fibrosis, respiratory tract infections, including viral infections, COVID-19, inflammatory diseases, metabolic diseases and other therapeutic applications. Pharmena S.A. was founded in 2002 and is based in Lódz, Poland. Pharmena S.A. operates as a subsidiary of Pelion S.A.
Share Price
$0.88679187
Market Cap
$9.88M
Change (1 day)
-1.56%
Change (1 year)
-7.31%
Country
PL
Trade Pharmena S.a. (PHR)

Category

Healthcare
Revenue for Pharmena S.a. (PHR)
Revenue in Aug 2026 TTM: 0
According to Pharmena S.a. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Pharmena S.a. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE